Switch theme
Sign up to access all valuation multiples
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
1998
40
LTM Revenue $0.7M
Last FY EBITDA -$32.5M
-$13.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Vistagen Therapeutics has a last 12-month revenue (LTM) of $0.7M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Vistagen Therapeutics achieved revenue of $1.1M and an EBITDA of -$32.5M.
Vistagen Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Vistagen Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.7M | XXX | $1.1M | XXX | XXX | XXX |
| Gross Profit | $0.7M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$32.5M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -3050% | XXX | XXX | XXX |
| EBIT | -$61.7M | XXX | -$33.0M | XXX | XXX | XXX |
| EBIT Margin | -8836% | XXX | -3103% | XXX | XXX | XXX |
| Net Profit | -$57.7M | XXX | -$29.4M | XXX | XXX | XXX |
| Net Margin | -8261% | XXX | -2760% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Vistagen Therapeutics's stock price is $3.
Vistagen Therapeutics has current market cap of $73.6M, and EV of -$13.2M.
See Vistagen Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$13.2M | $73.6M | XXX | XXX | XXX | XXX | $-1.73 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Vistagen Therapeutics has market cap of $73.6M and EV of -$13.2M.
Vistagen Therapeutics's trades at -16.6x EV/Revenue multiple, and 0.3x EV/EBITDA.
Equity research analysts estimate Vistagen Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Vistagen Therapeutics has a P/E ratio of -1.3x.
See valuation multiples for Vistagen Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $73.6M | XXX | $73.6M | XXX | XXX | XXX |
| EV (current) | -$13.2M | XXX | -$13.2M | XXX | XXX | XXX |
| EV/Revenue | -19.0x | XXX | -16.6x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 0.3x | XXX | XXX | XXX |
| EV/EBIT | 0.2x | XXX | 0.3x | XXX | XXX | XXX |
| EV/Gross Profit | -19.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.3x | XXX | -1.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialVistagen Therapeutics's last 12 month revenue growth is 138%
Vistagen Therapeutics's revenue per employee in the last FY averaged $27K, while opex per employee averaged $0.9M for the same period.
Vistagen Therapeutics's rule of 40 is -5126% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Vistagen Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Vistagen Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 138% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -5126% | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $27K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1882% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 3203% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vistagen Therapeutics acquired XXX companies to date.
Last acquisition by Vistagen Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Vistagen Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Vistagen Therapeutics founded? | Vistagen Therapeutics was founded in 1998. |
| Where is Vistagen Therapeutics headquartered? | Vistagen Therapeutics is headquartered in United States of America. |
| How many employees does Vistagen Therapeutics have? | As of today, Vistagen Therapeutics has 40 employees. |
| Who is the CEO of Vistagen Therapeutics? | Vistagen Therapeutics's CEO is Mr. Shawn K. Singh, J.D.. |
| Is Vistagen Therapeutics publicy listed? | Yes, Vistagen Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Vistagen Therapeutics? | Vistagen Therapeutics trades under VTGN ticker. |
| When did Vistagen Therapeutics go public? | Vistagen Therapeutics went public in 2009. |
| Who are competitors of Vistagen Therapeutics? | Similar companies to Vistagen Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Vistagen Therapeutics? | Vistagen Therapeutics's current market cap is $73.6M |
| What is the current revenue of Vistagen Therapeutics? | Vistagen Therapeutics's last 12 months revenue is $0.7M. |
| What is the current revenue growth of Vistagen Therapeutics? | Vistagen Therapeutics revenue growth (NTM/LTM) is 138%. |
| What is the current EV/Revenue multiple of Vistagen Therapeutics? | Current revenue multiple of Vistagen Therapeutics is -19.0x. |
| Is Vistagen Therapeutics profitable? | Yes, Vistagen Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
